Specialized services offered by end-to-end service providers are essential when dealing with the complex manufacture of drug products.
Often, the success of a development project can be significantly enhanced when early and careful planning for the future of a drug product is part of the strategy. Startups that pursue projects from the very start with packaged final products being the end goal can also attract the financial assistance of large companies and possibly out-licensing deals or acquisitions.
However, for small and large drug developers alike, employing a variety of service providers for different phases of the development and commercialization cycle can increase both cost and risk due to the need for lengthy technology transfer activities.
A better option may well be an end-to-end partner. A key benefit of such an approach is that the knowledge gained during early development work is retained and applied during late-stage process development.
Comprehensive services to meet customer needs
Vetter is a globally operating contract development and manufacturing organization (CDMO) that has long-term experience with small, midsize and large pharma and biotech companies.
With services ranging from early development support, including clinical manufacturing, to commercial supply and various packaging solutions, the company specializes in the aseptic manufacturing of prefilled syringes, cartridges and vials.
Vetter has extensive experience with monoclonal antibodies, peptides, interferons, vaccines and other complex compounds. Its innovative processes and state-of-the-art technologies can improve product quality and maximize API yields.
Vetter Development Service partners with customers from preclinical development through phase 3 and includes planning for commercial production from a product’s earliest stages. Its services include formulation support, process development, clinical trial manufacturing, as well as analytical and regulatory support. At its facilities, Vetter Development Service develops at an early stage scalable processes that enable later product transfers to its large-scale manufacturing.
Vetter Commercial Manufacturing provides phase 3 manufacturing through to global market supply. Vetter’s wide-ranging services deliver quality across the entire supply chain, including fill & finish, analytical services, regulatory support and product lifecycle management activities. To strengthen security of supply which includes regular quality reviews of suppliers and cross-linked IT systems to monitor manufacturing processes, the company backs its services downstream and upstream.
Vetter Packaging Solutions matches customer products with appropriate drug-delivery systems (primary packaging). It also offers customized packaging development, specialized technologies, and platform technologies. Secondary packaging such as cartoning or blister packing and other packaging services are offered including pen system assembly, printing and labeling and serialization.
Clinical manufacturing is performed at its dedicated facility in Chicago, U.S., in addition to Ravensburg, Germany, where Vetter operates three commercial facilities, a secondary packaging facility and a center for visual inspection and logistics.
Headquartered in Ravensburg, Germany, Vetter is a global leading contract development and manufacturing organization (CDMO) with production facilities in Germany and the United States.
Currently employing 4,500 people worldwide, the company has long-term experience in supporting biotechnology and pharmaceutical customers both large and small. Vetter services range from early stage development support including clinical manufacturing, to commercial supply and numerous packaging solutions for vials, syringes and cartridges.
As a leading solution provider, Vetter appreciates its responsibility to support the needs of its customers by developing devices that contribute to increased patient safety, convenience, and enhanced compliance. Great importance is also given to social responsibility, including environmental protection and sustainability.
<© Korea Biomedical Review, All rights reserved.>